Brief Report Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.2.012
Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
Muhammad Wasif Saif1,2,*, Hilal Hachem2, Sneha Purvey2, Ruchi Hamal2, Lulu Zhang2, Nauman Saleem Siddiqui2, Amandeep Godara2, Robert B. Diasio3
- 1Northwell Health Cancer Institute, Lake Success, NY 11042, USA
- 2Tufts Medical Center, Boston, MA, 02110, USA
- 3Mayo Clinic, Rochester, MN, Rochester, MN, USA
Corresponding Author
Muhammad Wasif Saif,wsaif@northwell.edu
Received Date: June 25, 2020
Accepted Date: August 05, 2020
Citation:
Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddique NS, et al. Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Arch Pharmacol Ther. 2020; 2(1):6-8.
Copyright: © 2020 Saif MW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
5-Fluorouracil, Capecitabine, Fluoropyrimidines, DPYD gene